BACKGROUND: The anti-programmed death-1 (anti-PD-1) therapy nivolumab has significant clinical activity in @entity1 with @entity320 . However, little is known about the safety and outcomes in patients receiving anti-PD-1 therapy and stereotactic radiation for the treatment of brain metastases (BMs). @entity1 AND METHODS: Data were analyzed retrospectively from two prospective nivolumab protocols enrolling 160 @entity1 with advanced resected and unresectable @entity320 at a single institution. @entity1 were included if BMs were diagnosed and treated with stereotactic radiation within 6 months of receiving nivolumab. The primary end point of this study was @entity2359 ; secondary end points included BM control and survival. RESULTS: Twenty-six @entity1 with a total of 73 BMs treated over 30 sessions were identified. Radiation was administered before, during and after nivolumab in 33 lesions (45%), 5 lesions (7%), and 35 lesions (48%), respectively. All BMs were treated with stereotactic radiosurgery (SRS) in a single session except 12 BMs treated with fractionated stereotactic radiation therapy, nine of which were in the postoperative setting. One @entity1 experienced grade 2 @entity10 following SRS with symptomatic relief with @entity479 treatment. No other treatment-related neurologic @entity137 or scalp reactions were reported. Eight (11%) local BM failures with a >= 20% increase in volume were noted. Of these lesions, @entity548 was noted in 4, and @entity4 was noted in 7. Kaplan-Meier estimates for local BM control following radiation at 6 and 12 months were 91% and 85%, respectively. Median @entity1349 ( @entity1349 ) from the date of stereotactic radiation and nivolumab initiation was 11.8 and 12.0 months, respectively, in @entity1 receiving nivolumab for unresected disease (median @entity1349 was not reached in @entity1 treated in the resected setting). CONCLUSIONS: In our series, stereotactic radiation to @entity320 BMs is well tolerated in @entity1 who received nivolumab. BM control and @entity1349 appear prolonged compared with standard current treatment. Prospective evaluation is warranted.

Clinical outcomes of XXXX brain metastases treated with stereotactic radiation and anti-PD-1 therapy.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage'] @entity4 :: ('MESH:D004487', 'Disease') :: ['edema'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival'] @entity10 :: ('MESH:D006261', 'Disease') :: ['headaches'] @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'metastatic melanoma'] @entity2359 :: ('MESH:D020258', 'Disease') :: ['neurotoxicity'] @entity479 :: ('D013256', 'Chemical') :: ['steroid']
@entity320 :: (MESH:D008545,Disease) :: ['melanoma']
